Literature DB >> 17016627

The effects of macrophage migratory inhibitory factor on acute-phase protein production in primary human hepatocytes.

Nicholas M Wheelhouse1, Nabil Dowidar, Cornelis H C Dejong, O James Garden, James J Powell, Matthew D Barber, Kathryn Sangster, Jean P Maingay, James A Ross.   

Abstract

Macrophage inhibitory factor (MIF) is a pituitary peptide released during the physiological stress response, a T-cell product secreted during the antigen-specific response and a pro-inflammatory macrophage cytokine secreted after LPS stimulation. It has become apparent that MIF is central to the regulation of the inflammatory response and is implicated in the pathogenesis of a variety of acute and chronic inflammatory conditions. This is, at least in part, due to the apparent counter-regulation of the anti-inflammatory actions of glucocorticoids, including the reversal of glucocorticoid-mediated IL-6 release inhibition. This study examines the effect of recombinant MIF on regulation of the acute phase response in isolated human hepatocytes. MIF alone increased C-reactive protein (CRP) release in a dose-dependent manner < or = 0.1 ng/ml after which the effects of MIF were attenuated. In combination with IL-6 both CRP and and alpha-1-antichymotrypsin (ACT) release were increased above levels found with either IL-6 or MIF treatment alone. Dexamethasone attenuated the effects of MIF upon CRP production but increased the MIF stimulated release of ACT. The study demonstrates that the effects of MIF upon the acute phase response are complex and can differentially modulate the production of acute phase proteins depending on the presence of other factors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17016627

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  5 in total

1.  Serum levels of macrophage migration inhibitory factor are associated with rheumatoid arthritis course.

Authors:  Mara Anaís Llamas-Covarrubias; Yeminia Valle; Rosa Elena Navarro-Hernández; Iris Paola Guzmán-Guzmán; María Guadalupe Ramírez-Dueñas; Héctor Rangel-Villalobos; Ciro Estrada-Chávez; José Francisco Muñoz-Valle
Journal:  Rheumatol Int       Date:  2011-05-24       Impact factor: 2.631

2.  Macrophage migration inhibitory factor (MIF) promoter polymorphisms (-794 CATT5-8 and -173 G>C): association with MIF and TNFα in psoriatic arthritis.

Authors:  Ramsés Morales-Zambrano; Luis A Bautista-Herrera; Ulises De la Cruz-Mosso; Guadalupe D Villanueva-Quintero; Jorge R Padilla-Gutiérrez; Yeminia Valle; Isela Parra-Rojas; Héctor Rangel-Villalobos; Sergio R Gutiérrez-Ureña; José F Muñoz-Valle
Journal:  Int J Clin Exp Med       Date:  2014-09-15

3.  Macrophage migration inhibitory factor may contribute to vasculopathy in systemic sclerosis.

Authors:  Heidemarie Becker; Peter Willeke; Heiko Schotte; Wolfram Domschke; Markus Gaubitz
Journal:  Clin Rheumatol       Date:  2008-07-11       Impact factor: 2.980

4.  Highly efficient differentiation of hESCs to functional hepatic endoderm requires ActivinA and Wnt3a signaling.

Authors:  David C Hay; Judy Fletcher; Catherine Payne; John D Terrace; Ronald C J Gallagher; Jan Snoeys; James R Black; Davina Wojtacha; Kay Samuel; Zara Hannoun; Anne Pryde; Celine Filippi; Ian S Currie; Stuart J Forbes; James A Ross; Philip N Newsome; John P Iredale
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-21       Impact factor: 11.205

5.  Discovery and validation of a colorectal cancer classifier in a new blood test with improved performance for high-risk subjects.

Authors:  Lisa J Croner; Roslyn Dillon; Athit Kao; Stefanie N Kairs; Ryan Benz; Ib J Christensen; Hans J Nielsen; John E Blume; Bruce Wilcox
Journal:  Clin Proteomics       Date:  2017-07-25       Impact factor: 3.988

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.